- Goals for information for 5-12 year-olds in July, says CEO.
- Sees outcomes for these as younger as six months in Sept.
- Expects to file for EMA approval for 12-15-year-olds quickly.
BERLIN: BioNTech expects outcomes by September from trials testing the COVID-19 vaccine that it and Pfizer have developed for infants as younger as six months outdated, German journal Spiegel cited the corporate’s CEO as saying.
“In July, the first results could be available for the five to 12 year olds, in September for the younger children,” BioNTech Chief Government Ugur Sahin advised Spiegel. He added it takes about 4 to 6 weeks to guage the info.
“If all goes well, as soon as the data is evaluated, we will be able to submit the application for approval of the vaccine for all children in the respective age group in different countries,” he stated.
BioNTech and Pfizer requested US regulators this month to approve emergency use of their vaccine for adolescents aged 12 to fifteen.
Sahin was quoted by Spiegel as saying the corporate was “in the final stages before submission” to European regulators for youngsters aged 12 and older.
A trial printed on the finish of March discovered the businesses’ COVID-19 vaccine was protected, efficient and produces sturdy antibody responses in adolescents.
The Pfizer/BioNTech two-shot vaccine is already approved to be used in these aged 16 and above.
Younger individuals are much less prone to endure extreme circumstances of COVID-19 and extra prone to have asymptomatic an infection, permitting them to unwittingly transmit COVID-19 to others.